Auner, H. W., Szydlo, R., Hoek, J., Goldschmidt, H., Stoppa, A. M., Morgan, G. J., Moreau, P., Attal, M., Marit, G., Russell, N., Brune, M., Cook, G., Sonneveld, P., Schonland, S., Garderet, L., Kroger, N., European Soc, Blood, Marrow, Transp (2015) Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. BONE MARROW TRANSPLANTATION, 50 (2). pp. 209-215. ISSN 0268-3369

Full text not available from this repository.

Abstract

Autologous hematopoietic cell transplantation (AHCT) is a standard of care in multiple myeloma (MM) patients aged <65 years. To understand age-related trends in utilisation and outcome of AHCT, we analysed 53 675 MM patients who underwent a first AHCT in 31 European countries between 1991 and 2010. The number of patients undergoing AHCT increased for all age groups (<40, 40-49, 50-59, 60-64, 65-69 and. 70 years) throughout the observation period. The highest increase was observed for patients aged. 65 years, who accounted for 3% of AHCTs in 1991-1995 and for 18.8% of AHCTs in 2006-2010. Risk factors associated with survival over the entire observation period (P<0.001) were calendar period, remission status at AHCT, gender, disease duration before AHCT and age. Survival improved considerably more in older than in younger patients in recent years. In 2006-2010, median 2- and 5-year post-transplant survival ranged from 85.9 and 61.5% in patients <40 years to 80.2 and 49.7% in those >= 70 years. All-cause day-100 mortality decreased throughout the observation period to <= 2.4% for all age groups in 2006-2010. The results of this study demonstrate increased utilisation and safety of AHCT with improved post-transplant survival particularly in elderly MM patients in recent years in Europe.

Item Type:	Article
Authors (ICR Faculty only):	Morgan, Gareth
All Authors:	Auner, H. W., Szydlo, R., Hoek, J., Goldschmidt, H., Stoppa, A. M., Morgan, G. J., Moreau, P., Attal, M., Marit, G., Russell, N., Brune, M., Cook, G., Sonneveld, P., Schonland, S., Garderet, L., Kroger, N., European Soc, Blood, Marrow, Transp
Additional Information:	ISI Document Delivery No.: CB1QM Times Cited: 0 Cited Reference Count: 41 Auner, H. W. Szydlo, R. Hoek, J. Goldschmidt, H. Stoppa, A. M. Morgan, G. J. Moreau, P. Attal, M. Marit, G. Russell, N. Brune, M. Cook, G. Sonneveld, P. Schonland, S. Garderet, L. Kroger, N. Celgene; Janssen; Onyx HG has been a consultant for Janssen, Celgene, Novartis, Onyx and Millennium, has received honoraria from Janssen, Celgene, Novartis, Onyx, Chugai and Millennium, and has received research funding from Janssen, Celgene, Novartis and Chugai. GM has received remuneration from Janssen and Celgene. PM has been a consultant for and received honoraria from Celgene, Janssen, and Millenium. SS has received honoraria from Celgene and Janssen and research funding from Celgene. PS has received honoraria and research funding from Celgene, Janssen and Onyx. The remaining authors declare no conflict of interest. Nature publishing group London
Uncontrolled Keywords:	bone-marrow-transplantation high-dose chemotherapy randomized-trial younger patients survival melphalan era therapies age epidemiology
Research teams:	ICR divisions > Clinical Studies > Molecular Haematology (including Cytogenetics Group and Cell Markers) ICR divisions > Molecular Pathology > Molecular Haematology (including Cytogenetics Group and Cell Markers)
Depositing User:	Alexander Smithson
Date Deposited:	16 Mar 2015 14:00
Last Modified:	16 Mar 2015 14:00
URI:	http://publications.icr.ac.uk/id/eprint/13936

Actions (login required)

View Item